1. CEL-SCI Corporation
NYSE AMEX: CVM
Geert Kersten
Chief Executive Officer
8229 Boone Boulevard, Suite 802
Vienna, VA 22182, USA
Phone: (703) 506-9460

2. Forward-Looking Statements
Statements made during the course of this presentation that state the Company’s
or management’s intentions, hopes, beliefs, expectations or predictions of the
future are forward-looking statements. It is important to note that the Company’s
actual results could differ materially from those projected in such forward-looking
statements. This presentation only highlights some of the progress CEL-SCI has
made to date. It is not meant to be a complete document as it forms only the
visual basis of the company’s presentation.
Additional information in general and concerning factors that could cause actual
results to differ materially from those in the forward-looking statements is
contained from time to time in the Company’s SEC filings, including but not
limited to the Company’s report on Form 10-K for the year ended September 30,
2011. Copies of this presentation may be obtained by contacting the Company.
2

3. Explanatory Statement
Multikine is the trademark that CEL-SCI has registered for this investigational
therapy, and this proprietary name is subject to FDA review in connection with
our future anticipated regulatory submission for approval. Multikine has not been
licensed or approved for sale, barter or exchange by the FDA or any other
regulatory agency. Similarly, its safety or efficacy has not been established for
any use. Moreover, no definitive conclusions can be drawn from the early-phase,
clinical-trials data summarized in this presentation involving the investigational
therapy Multikine (Leukocyte Interleukin, Injection). Further research is required,
and early-phase clinical trial results must be confirmed in the well-controlled
Phase III clinical trial of this investigational therapy that is currently in progress.
Each page of this presentation must be looked at in the context of the whole
presentation, not by itself, and is merely meant to be a summary of the full and
detailed information on the Company in its public filings and its website.
Potential conclusions could only be drawn if the initial observations in the early-
phase studies relating to the potential adverse events associated with Multikine
administration in treating head and neck cancer are confirmed in the well
controlled Multikine Phase III clinical study, CEL-SCI's Phase III study is
completed successfully, and the FDA licenses the product following their review of
all of the data related to Multikine submitted in CEL-SCI's license application.
3

4. CEL-SCI Stock Summary
• Name of Company: CEL-SCI Corporation
• Location: Washington, D.C. (USA) metro area
• Stock symbol: NYSE AMEX: CVM
• Shares outstanding: 230 million
• Current valuation: About $70 million
• Average daily trading volume, last 30 days: About 500,000
• 52 week range: $0.27 - $1.05
4

5. Product Pipeline
CANDIDATE PRECLINICAL PHASE I PHASE II PHASE III SALES
MULTIKINE
Head and Neck Cancer (first-line)
Cervical Cancer
Enhancement of
radiation/chemotherapy
L.E.A.P.S. Technology
Pandemic Flu treatment
Rheumatoid Arthritis CEL-2000
Malaria
Viral Encephelities
Herpes
5

6. Multikine Cancer Immunotherapy
Summary of ”What is Multikine”
What is Multikine?
• Is an investigational immunotherapy drug consisting of 14 cytokines.
• Is being tested in a global Phase III clinical trial to determine its effectiveness
against advanced primary head and neck cancer (US orphan drug status).
• Has a unique mechanism of action.
• Is given for 3 weeks BEFORE any other cancer therapies (surgery, radiation and/or
chemotherapy) because that would appear to be the best time to produce an
effective immune response.
• Teva Pharmaceuticals (Israel) and Orient Europharma (Taiwan) are partners and
participate in the Phase III trial.
• Multikine, once approved for sale, would be mass produced in the Company’s
existing manufacturing plant.
• Multikine uses the patient’s own tumor antigens to provide specificity for the anti-
tumor immune response.
• The primary focus of Multikine is to eliminate the micro-metastases, believed to be
the cause of cancer recurrence.
6

7. Multikine Cancer Immunotherapy
Next Class of Immunotherapy Drugs
Multikine represents the next class of generation immunotherapy drugs because:
1) Multikine is given before any other cancer therapy – optimal time, biggest
market.
2) Multikine contains both active and passive immunity and therefore does not
require an outside antigen.
3) Multikine is mass produced at the Company’s manufacturing facility. It is NOT
made from the patient’s own blood and/or tumor – reasonable price with excellent
profit margin.
7

8. Clinical Development of Multikine
Multikine – Lead Indication is First-Line H&N Cancer
• Locally advanced primary head & neck cancer patients
• Current standard of care as defined by the NCCN Clinical Practice Guidelines
in Oncology, Head and Neck Cancer, is:
 Surgery followed by Radiation Therapy (+/- Chemo)
• Upon the success of the Multikine Phase III study and approval by the FDA
and other regulatory agencies, one would expect that doctors will elect to
give Multikine to head and neck cancer patients ahead of surgery.
Multikine Treatment Surgery Radiation Therapy (+/- Chemo)
8

9. Initial target market
Head and neck cancer:
6% of all cancers, or about 650,000 new cases annually worldwide, 150,000 of
those are in the US and EU. About 2/3 of these head and neck cancer patients have
advanced primary disease.
• Unmet medical need.
• Uniform standard of care world-wide for advanced primary head and neck
cancer.
• Approval could potentially lead to Multikine becoming part of the standard of
care treatment along with the first treatment of surgery, radiation and chemo
(first line standard of care).
• Multi-billion $ market opportunity.
• Likelihood of world-wide approval on successful single Phase III study.
9

10. Multikine
“Proof of Concept” Phase II Results
• Summary of “Proof of Concept” Phase II results using the same treatment schedule as
is being used in Phase III study
Multiple studies were conducted to select the final treatment regimen
 Improvement in overall survival at 3.5 years (J. Oral Oncology; n=19)
 Long term survival in Multikine treated group (n=19) was 63.2%
 Long term survival of all patients in literature (n=7,294) was 47.5%
 No Severe Adverse Events related to Multikine (All Phase I/II Studies to date:
n=220)
 No deaths related to Multikine (All Phase I/II Studies to date: n=220)
 Phase I/II studies conducted in US, Canada, Europe and Israel
Impact of Multikine (after 3 week treatment, PRIOR to surgery)
 12% of the patients had no tumor after only Multikine treatment (by pathology)
(ASCO and Journal of Clinical Oncology; MK Treated n=19: 17 SCC; CR 2, PR 4 by
RECIST)
 50% reduction in the number of tumor cells after only Multikine treatment (by
pathology) (Journal of Clinical Oncology; n=19)
Additional and confirmatory survival, pathology and tumor response data published
in:
– Archives of Otolaryngology August 2003 (Feinmesser et al) (n=12)
– The Laryngoscope Dec. 2003 (Timar et al) (n=54)
10

11. Multikine Clinical Development
Phase I-II Safety Profile
• In safety and dose finding studies:
During the early investigational phase, in Phase I and Phase II clinical trials in
a total of over 220 subjects who received the investigational therapy Multikine
in daily doses of 200 to 3200 IU as IL-2 (over 2-3 weeks in Phase II and up to
a few months in early-Phase I), no serious adverse events were reported by
the clinical investigators as being expressly due to administration of this
investigational therapy Multikine. Adverse events which were reported
included pain at the injection site, local minor bleeding and edema at the
injection site, diarrhea, headache, nausea, and constipation. No "abnormal"
laboratory results were reported following Multikine treatment - other than
those commonly seen by treating physicians in this patient population -
regardless of Multikine administration. Similarly, in these early-phase clinical
studies in patients, there was no reported increased toxicity of follow-on
treatments as a result of Multikine administration. No complications following
surgery (such as increased time for wound healing) were reported.
11

12. Multikine
Multikine Potential Treatment Effect – Changes in Tumor Microenvironment
Oral Squamous Cell Carcinoma
(Locally Advanced Primary H&N Cancer)
Histological appearance of necrosis in Oral Squamous Cell Carcinoma (OSCC)
[HE staining]:
Non-Multikine treated Multikine treated
Non-Multikine treated: Lack of necrosis in the epithelial nests of OSCC
Multikine treated: Entire cancer nest is necrotic and filled with debris and leukocytes
This complete destruction of the tumor was seen in only 12% of the patients
* Modified from Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005
12

13. Multikine
Mechanism of action
Tumoricidal / Tumoristatic Multikine
(perilymphatic)
Necrosis Local / Regional
(e.g., TNF)
Antigen Presenting Cells
(Dendritic Cells, Macrophages)
Micro Metastases
Lymph
Neutrophils
Nodes
Multikine Tumor
(peritumoral) CD4 + T Cells
CD8 + T Cell
Micro
Chemotactic Metastases
(e.g., IL-6, IL-8)
Lymphoproliferative
(e.g., IL-2)
Source: Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005 13

14. Multikine Treatment Effect
A Paradigm Shift in Tumor Microenvironment
CD4 MK Treated (n=17)
MK Treated
CD4/CD8 > 2.5
CD8 P<0.05 [+2 CR]
P<0.05
CD4 Control (n=20)
Control CD4/CD8 < 0.5
CD8
0 50 100 150
Density of cells/HPF
(Mean ± SEM)
Multikine Treatment Effect on Host CD4 and CD8 Tumor Infiltrating Cell Density in OSCC
(Locally Advanced Primary H&N Cancer)
* Talor et al., ASCO Annual Meeting Proceedings 22(14S): 189S, 2004
Timar et al., Journal of Clinical Oncology 23(15) May 20, 2005 14

15. Multikine T cells
How Multikine circumvents the tumor defense mechanisms!
LYMPH
CD8+ T-cells and NK cells not treated with Multikine
are “blocked” by the tumor. Therefore they are unable NODE
to trigger a potential anti-tumor immune response.
No potential anti-
No potential anti- T
tumor response DC cells
tumor response
DC
Class I Class I
NK Tumor CD8
Cells CTL
Inhibition
No Activation
NKR Class II ?
15

16. Multikine T cells
How Multikine circumvents the tumor defense mechanisms!
LYMPH
Following Multikine administration tumor-specific
activated CD4+ helper T cells “rescue” and activate NODE
tumor residing NK cells, which then trigger a potential
anti-tumor response.
T
DC cells
No potential anti- DC
tumor response
Class I Class I
NK Tumor CD8
Cells CTL
(Activated) No Activation
NKR Class II ?
IL-2, IFN-γ
TCR
CD4
(Activated)
Help (Including MIP-1α)
IL-2, 16
IFN-γ

17. Multikine: Phase III trial
One pivotal Phase III trial
• Advanced primary (not yet treated) head & neck cancer represents an unmet
medical need (about 50% of the patients die within 3 years following
treatment) with minimal progress over the last 50 years.
• FDA, Canadian and seven other regulators on three continents gave go-ahead
to Multikine Phase III study.
• Effort was led by CEL-SCI’s Senior VP of Regulatory Affairs, John Cipriano, MS,
RPh, who was the prior Deputy Director, Division of Biologics Investigational
New Drugs, Office of Biologics Research and Review at the FDA.
• Orphan drug designation in the US codifies that only one trial should be
needed.
17

18. Multikine Phase III trial
Phase III Trial
• USA, Canada, Hungary, Poland, Russia, Israel, India and Taiwan. Started the study
in all 8 countries to date.
• Planned enrollment: 880 patients.
• To date, 36 centers have passed SIV and are screening/accruing patients; goal is to
reach about 50 centers in total.
• Partners in Phase III study:
Israel - Teva Pharmaceuticals.
Taiwan- Orient Europharma of Taiwan.
• Primary endpoint = 10% improvement in overall survival.
• Event-driven study.
• NIH participation for measurement of genetic and molecular markers of patients.
18

19. Multikine: Phase III trial
Study Design and Statistical Parameters
Methodology:
• Phase III open-label, randomized, controlled, multi-center study.
 Enroll about 880 patients to have about 780 evaluable patients.
 Reference Therapy: Standard of Care = Surgery + Radiation +/-
Chemotherapy.
 Three (3) week administration of Multikine + standard of care and median
three year follow-up (event–driven).
 Primary end point: Overall Survival.
Statistics:
• 80% Power; 95% confidence - to show a 10% Overall Survival advantage.
19

20. Multikine Phase III Schematic Randomization and
Treatment of Enrolled Patients
R Group 1 (approx. 377 pat.) RTx
Standard of Care S**
E A
U Radiotherapy (60 - 70 Gy,
N N 3 30 - 35 fractions over 6 - 7 Weeks)
D Group 2 (approx. 377 pat.) R
R Multikine 5X/week for 3 weeks
-OR-
O 3 (+ CIZ*) G
O
L M E CRTx
I R
L Z Group 3 (approx. 125 pat.) *** High Risk: Concurrent
Multikine 5X/week for 3 weeks radiochemotherapy (60 – 70) Gy, 30 - 35
1 Y fractions, over 6-7 weeks + IV cisplatin
E (No CIZ)
(Dose 100 mg/m2) 1X per week on first
day of weeks 1, 4, 7 of RTx
The overall survival comparison will be made between groups 1 and 2. The primary purpose of the
smaller Group 3 is to gain more information on the mechanism of action of Multikine. CIZ is added to
decrease tumor suppressor mechanisms and thereby increase Multikine effectiveness.
* CIZ: Cyclophosphamide 300 mg/m2 (x1,IV, day -3); Indomethacin 25mg tid, po (day 1 to 24 hrs prior to surgery) + 15-45mg Zinc (as Multivitamin) i.d., p.o.
** Surgery: complete surgical resection of primary tumor and any positive lymph nodes.
*** High risk patients are defined as those with: positive surgical margins, 2 or more
clinically positive nodes, or extra capsular nodal spread (any or all of the above).

21. Multikine Phase III trial
Purpose of Multikine + CIZ and Multikine without CIZ study arms
CIZ Arm - CIZ included to enhance Multikine activity
• Cyclophosphamide - low (non-chemotherapeutic) dose decreases tumor
suppressor cells (Berd Cancer Res. 1984, 1986; North J. Exp. Med 1982;
Kameda Int. J. Immunother. 1992; Timar JCO 2005)
• Indomethacin - Low dose indomethacin retards the secretion of
prostaglandin E-2 (PGE-2) by tumor residing monocytes/macrophages a
potent inhibitor of lymphocyte proliferation (Feinmesser Arch Otolaryngol
H&N Surg 2003).
• Zinc - known to increase activation of thymus factors associated with
increased T cell activity.
Non-CIZ Arm – Included to attempt to determine the extent of the contribution of
CIZ to Multikine effects.
21

22. Multikine Phase III trial
Large Phase III Study Designed To Position Multikine As Part of the Standard of Care
• World-wide: Eight countries on three continents: North America, Europe, Asia.
• Largest pathology study ever done in head and neck cancer.
• Partners enrolling in the study:
Israel - Teva Pharmaceuticals.
Taiwan- Orient Europharma of Taiwan.
• Subjects enrolled in approximate proportion to world distribution of the disease.
• Expect rapid enrollment and relatively fast results.
• NIH participation for measurement of genetic and molecular markers of
patients (personalized medicine).
22

23. Multikine Phase III trial
Preparation and Management of Large Global Phase III Trial
Attention to detail is key:
• Radiation qualifications conducted by RPC (MD Anderson Cancer Center, The
University of Texas).
• Central Imaging qualifications conducted by a leading US company specializing
in Clinical Trial Imaging.
• Central Pathology Laboratory.
• All study drugs (e.g. chemotherapy) are sourced from same place only.
• Cold shipping around the world provided by leading US company with fully
validated containers.
23

24. Multikine IP
Intellectual property protection
Patents and other protection for Multikine:
• Composition of matter patent protection until 2024.
• US Patent # 6,896,879 and European Patent # 1,773,395.
• Additional pending patent applications world-wide.
• Orphan drug designation in US gives 7 year market exclusivity.
• Proprietary manufacturing and quality control know-how (most important
since Multikine is a complex biologic and practically impossible to copy).
24

25. Multikine Manufacture
Steps to improve risk/reward
• Commercial sized $25 million manufacturing facility outside Baltimore,
Maryland, USA.
• Facility includes True Cold Fill (+4°C) capability to avoid loss of biological
activity during fill.
• Successful EU Audit in Fall 2010:
CEL-SCI Corporation's Manufacturing and Laboratory Operations
Deemed Compliant with GMP Requirements Following Audit by
European Union Qualified Person.
• Facility will supply Phase III study and subsequent commercial sale.
 Current capacity about 20,000 treatments annually.
 Fully built out capacity about 60,000 treatments annually.
25

26. Multikine Phase III partners
Steps to improve shareholder reward/risk prospects
Retain head and neck cancer indication rights for the US and Europe, offering
shareholders the full upside potential.
Additional partnerships are anticipated outside of US/EU and for other tumor
indications.
CEL-SCI’s current partners funding and participating in Phase III trial:
• Teva Pharmaceuticals of Israel (Territories: Israel and Turkey, added
Serbia and Croatia in summer of 2011).
 Teva will run and pay for part of the Phase III trial in Israel.
 Revenue share upon sale.
• Orient EuroPharma (OEP) of Taiwan (Territories: parts of the Far East,
not Japan or China).
 OEP will run and pay for part of the Phase III trial in Taiwan.
 Revenue share upon sale.
26

27. Key Management Team
Business
Maximilian de Clara
• Founder, President and Chairman of the Board, CEL-SCI Corporation,
1983 - Present
• Personally funded research in the fields of biotechnology and biomedicine
• Awarded the "Pour le Merit" honorary medal of the Austrian Military Order
"Merito Navale"
• Awarded the Honor Cross of the Austrian Albert Schweitzer Society
Geert Kersten, MBA, JD
• Chief Executive Officer, CEL-SCI Corporation, 1987 – Present
Patricia B. Prichep
• Senior Vice President of Operations, CEL-SCI Corporation, 1992 – Present
• Manager, Quality and Productivity, National Association of Securities
Dealers (NASD), Rockville, MD, 1989 - 1992
27

28. Key Management Team
Science
Eyal Talor, PhD
• Chief Scientific Officer 2010 – Present
• Senior Vice President of Research and Manufacturing, CEL-SCI Corporation,
1994 – Present
• Director of R&D and Clinical Development, CBL, Inc., Baltimore, MD
• Principal Scientist - Project Director, Clinical Laboratory Director, SRA
Technologies, Inc.
• Adjunct Professor at Johns Hopkins University Medical Institutions
John Cipriano, MS, RPh
• Senior Vice President of Regulatory Affairs, CEL-SCI Corporation
• Deputy Director, Division of Biologics Investigational New Drugs, Office of
Biologics Research and Review, Food and Drug Administration (FDA)
• Deputy Director, IND Branch, Division of Biologics Evaluation, Office of
Biologics, Food and Drug Administration (FDA)
Daniel Zimmerman, PhD
• Senior Vice President of Research, Cellular Immunology, CEL-SCI
Corporation
• L.E.A.P.S. Technology Inventor
• Founder and President, CELL-MED, Inc., 1987 – 1995
• Scientist, Sr. Scientist, Technical Director and Program Manager,
Electronucleonics, Inc., 1973 – 1987
28

29. Key Management Team
Science
William “Brooke” Jones
• Vice President of Quality Assurance, CEL-SCI Corporation, 1999 – Present
• Director of Quality Control and Quality Assurance at the Systemix Facility in
Lyon, France, 1994 - 1997
• Management positions at Biogen, 1983 - 1991
• Head of GMP Compliance at Fort Detrick, NCI- Frederick Cancer Research
Center, 1979 - 1983
Todd Burkhart
• Vice President of Manufacturing/Facilities & Commercial Operations,
CEL-SCI Corporation, 2010 – Present
• 30 years of experience in the manufacture and process development of
biologics, medical devices and other Active Pharmaceutical Ingredients
(APIs)
• Previously ran a number of major pharmaceutical facilities at companies
such as Cephalon, Human Genome Sciences and Univax Biologics
29

30. Thank You